MODULE 1: Integration of Targeted Therapy and Immunotherapy into the Management of Metastatic Colorectal Cancer (mCRC) — Dr Ciombor

• Appropriate integration of encorafenib/cetuximab for patients with mCRC with BRAF V600E mutations; available results with and ongoing evaluation of earlier use of BRAF-targeted therapy
• Rational incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab into the treatment of microsatellite instability-high/mismatch repair-deficient mCRC
• Available clinical research findings with immune checkpoint inhibitor-based strategies in microsatellite-stable mCRC
• Current appreciation of predictors of response to immunotherapy in CRC; ongoing effort to validate the 27-gene expression test as a predictor of immunotherapy response in CRC and other gastrointestinal tumors
• Frequency of HER2 overexpression in patients with mCRC; available data with novel HER2-targeted therapies (eg, trastuzumab deruxtecan [T-DXd], tucatinib)
• Incidence of KRAS p.G12C mutations in mCRC; early results with and ongoing evaluation of KRAS G12C inhibitors (eg, sotorasib, adagrasib)

MODULE 2: Other Considerations in the Management of Localized and Advanced CRC — Dr Strickler

• Mechanistic rationale for and available data with longitudinal circulating tumor DNA (ctDNA) monitoring for patients with localized CRC
• Ongoing studies (eg, BESPOKE CRC) examining the clinical utility of ctDNA testing for monitoring recurrence and guiding treatment decisions
• Available data linking tumor sidedness to outcomes with EGFR antibody-based regimens for patients with mCRC
• Factors in the selection and sequencing of approved regimens for patients with mCRC whose disease has progressed on multiple lines of therapy; rational incorporation of regorafenib and TAS-102
• Available data with TAS-102 in combination with other systemic agents and in earlier disease stages
• Other promising novel agents and strategies for patients with mCRC

MODULE 3: Current and Future Treatment Paradigm for Gastroesophageal Cancers — Prof Van Cutsem

• Published outcomes from the Phase III CheckMate 577 study of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction (GEJ) cancer; appropriate selection of candidates for this strategy
• Published data sets (eg, CheckMate 649, CheckMate 648, KEYNOTE-590, ORIENT-15, ORIENT-16, JUPITER-06) supporting the efficacy and safety of first-line regimens combining anti-PD-1/PD-L1 antibodies with chemotherapy or other immunotherapies for advanced gastric, GEJ and esophageal cancers
• Principal outcomes from the Phase III KEYNOTE-811 trial supporting the use of first-line pembrolizumab/trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
• Published efficacy and safety data with T-DXd in Japanese (DESTINY-Gastric01 trial) and Western (DESTINY-Gastric02 trial) patients; sequencing of T-DXd for patients with progressive HER2-positive disease
• Optimal placement of ramucirumab and TAS-102 in current clinical algorithms; available data with novel ramucirumab- and TAS-102-containing combination regimens
• Mechanism of action of zolbetuximab; available findings with first-line zolbetuximab/chemotherapy in patients with advanced claudin 18.2-positive gastric/GEJ adenocarcinoma
• Other promising agents and strategies under investigation for gastroesophageal cancers

MODULE 4: Selection and Sequencing of Therapy for Advanced Hepatocellular Carcinoma (HCC) — Dr Philip

• Current clinical roles of sorafenib and lenvatinib as first-line therapy for unresectable HCC; patient selection for tyrosine kinase inhibitor monotherapy
• Long-term efficacy and safety findings supporting the use of first-line atezolizumab/bevacizumab for unresectable HCC; optimal integration into practice
• Results from the Phase III HIMALAYA study demonstrating an overall survival advantage with a single priming dose of tremelimumab added to durvalumab compared to sorafenib alone for previously untreated advanced HCC; clinical implications
• Available data with and ongoing evaluation of other novel combination strategies for HCC
• Long-term outcomes with approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) for patients with progressive HCC
• Published efficacy and safety data with and current clinical roles of single-agent immune checkpoint inhibitors and nivolumab/ipilimumab for relapsed/refractory disease
• Early data with neoadjuvant or adjuvant immunotherapy-based treatment for HCC and ongoing Phase III studies (eg, Checkmate 9DX, EMERALD-2, IMbrave050, KEYNOTE-937)

MODULE 5: Novel Treatment Strategies for Advanced Biliary Tract Cancers — Dr Bekaii-Saab

• Findings from the Phase III TOPAZ-1 trial evaluating durvalumab in combination with chemotherapy as first-line treatment for advanced biliary tract cancers; implications for clinical practice
• Spectrum of molecular alterations in cholangiocarcinoma and other biliary tract cancers; utility of genomic analyses to identify actionable molecular abnormalities
• Clinical trial findings supporting the FDA accelerated approvals of pemigatinib and infigratinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
• Efficacy and safety outcomes observed with other FGFR inhibitors (eg, futibatinib) in patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements
• Ongoing Phase III evaluations of FGFR inhibition for treatment-naïve cholangiocarcinoma (eg, FIGHT-302, PROOF, FOENIX-CCA3)
• Available efficacy and safety outcomes from the Phase III ClarIDHy study leading to the recent FDA approval of ivosidenib for cholangiocarcinoma with an IDH1 mutation; optimal integration into routine practice
• Ongoing research evaluating ivosidenib in combination with chemotherapy for newly diagnosed cholangiocarcinoma
• Early-phase data with HER2-targeted strategies (eg, T-DXd, zanidatamab) in HER2-positive biliary tract cancers
• Other promising novel agents and strategies for patients with advanced biliary tract cancers

MODULE 6: Contemporary Management of Pancreatic Cancer — Dr O’Reilly

• Clinical trials evaluating contemporary cytotoxic regimens with or without radiation therapy as preoperative therapy for resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
• Selection of adjuvant systemic therapy for patients with resected PAD
• Optimal selection of first- and later-line treatment for patients with metastatic PAD; importance of age, comorbidities and prior therapy
• Incidence of BRCA1/2 mutations and other DNA damage repair deficiencies in patients with PAD; guideline-endorsed algorithms for genetic testing
• Long-term efficacy and safety findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD and a germline BRCA mutation
• Available data with PARP inhibitors in combination with other anticancer therapies and/or in earlier disease stages
• Other novel agents and strategies under investigation for localized and advanced pancreatic cancer

Thank you for your interest in our CME program taking place in Chicago, IL. At this time ONLINE "IN-PERSON" PREREGISTERATION is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED - ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:30 PM Central Time on Saturday, June 4. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (702 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2022 ASCO Annual Meeting website.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.